Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0466 in advanced hematologic or solid tumors
NCT04214093Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD0466 in solid tumor (advanced stage), lymphoma, multiple myeloma (MM) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose Limiting Toxicities and Adverse Events at 6 months. Started Dec 2019; status: terminated.
02
Drugs
AZD0466
03
Conditions
solid tumor (advanced stage)lymphomamultiple myeloma (MM)hematologic malignancy
Beyond the preview
Go deeper on NCT04214093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214093.